Case Report: Glofitamab in the treatment of a patient with central nervous system-involved Burkitt lymphoma
Authors:
Open Access
- 17 February 2026
- journal article
- case report
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 16, 1724213
Abstract
Burkitt lymphoma (BL) is a rare and highly aggressive B-cell non-Hodgkin lymphoma. While targeted combination chemotherapy can be effective, it is associated with a high rate of relapsed or refractory disease and a pronounced propensity for central nervous system (CNS) involvement. Currently, novel therapies such as chimeric antigen receptor T-cell (CAR-T) therapy have not demonstrated established efficacy in BL. Given the poor prognosis and the challenge of managing relapsed/refractory BL, the use of bispecific antibodies, specifically glofitamab, as employed in this case, has yielded a favorable therapeutic outcome. This is particularly noteworthy in the present case, given the patient’s documented CNS infiltration. After the failure of first-line treatment in this case, the combination of glofitamab and a Bruton’s tyrosine kinase inhibitor (BTKi) was used for six cycles, which significantly improved the patient’s CNS infiltration and achieved a long remission period. This provides an opportunity to try glofitamab in the treatment of CNS lymphoma, and we look forward to its confirmation in more BL patients.Keywords
This publication has 20 references indexed in Scilit:
- Diagnosis and treatment of Burkitt lymphoma in adults: clinical practice guidelines from ERN-EuroBloodNetThe Lancet Haematology, 2025
- Burkitt lymphomaHuman Pathology, 2024
- Benefit with glofitamab plus chemotherapy in transplant-ineligible R/R DLBCLNature Reviews Clinical Oncology, 2024
- Glofitamab plus gemcitabine and oxaliplatin (GemOx) versus rituximab-GemOx for relapsed or refractory diffuse large B-cell lymphoma (STARGLO): a global phase 3, randomised, open-label trialThe Lancet, 2024
- Primary central nervous system lymphomaNature Reviews Disease Primers, 2023
- Burkitt lymphomaNature Reviews Disease Primers, 2022
- The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid NeoplasmsLeukemia, 2022
- CD20-TCB with Obinutuzumab Pretreatment as Next-Generation Treatment of Hematologic MalignanciesClinical Cancer Research, 2018
- MYC on the Path to CancerCell, 2012
- Trimodal age‐specific incidence patterns for Burkitt lymphoma in the United States, 1973–2005International Journal of Cancer, 2010